Don’t Feed the Shield: How Cancer Uses Antioxidants to Survive Treatment

If you or someone you love is going through cancer treatment, you may have asked a hard question: why does a treatment that should work sometimes stop working, or why does cancer sometimes come back? There is no single answer, but one important piece of the puzzle is a protective shield that many tumors build around themselves.

In this article, I’ll walk you through that shield in plain language. You do not need a science background. By the end, you will understand why cancer cells make so many protective chemicals called antioxidants, how those chemicals help cancer survive treatment, and what researchers are doing about it.

Sparks and Fire Extinguishers

Every cell in your body burns fuel to make energy, much of it inside tiny power plants called mitochondria. Oxygen is central to this process, which is why we need to breathe. As this furnace runs, a small share of the oxygen escapes in an unstable, “charged up” form. These escaped molecules are called reactive oxygen species, or ROS. You may also hear them called free radicals or oxidants. Throughout this article, I will call them sparks.

What makes ROS so reactive? Oxygen normally holds its electrons in stable pairs. ROS are forms of oxygen that are out of balance, so they grab electrons from nearby molecules. That grabbing is called oxidation, the same basic chemistry that rusts iron or turns a cut apple brown. ROS come in several forms. Some, like the hydroxyl radical, are fierce and last only a split second. Others, like hydrogen peroxide (the same chemical in the brown bottle in your medicine cabinet, though in far smaller amounts), are milder and can travel through the cell.

ROS are not all bad. In small amounts, your body uses them well. Cells use them as messengers to switch processes on and off, and your immune cells fire bursts of them to destroy germs. As you will read later, the T cells that fight cancer actually need a little ROS to switch on.

The trouble comes when there are too many. Excess ROS damage the cell’s DNA, its proteins, and the fatty wall that holds it together. When sparks outpace the cell’s defenses, doctors call it oxidative stress. If the damage is severe enough, the cell triggers its own self-destruct program.

To keep sparks in check, your cells have their own fire extinguishers, called antioxidants. In a healthy cell, sparks and extinguishers stay in careful balance: enough sparks to send useful signals, enough extinguishers to prevent damage. It is one of the many quiet ways your body protects itself every day.

Why Cancer Cells Build Extra Extinguishers

Cancer cells grow fast and burn fuel in unusual ways, so their furnaces run hot. They live with far more sparks than normal cells. Without change, all that heat would eventually destroy them.

So cancer cells adapt. They flip on a master switch (called NRF2) that tells the cell to build extra fire extinguishers, far more than a normal cell would ever need. In many tumors, the gene changes that drive the cancer are the very same ones that turn this switch on. The result is a cell that can live in the middle of a fire without burning up.

A Harsh Neighborhood

Fast growth is only half the story. A tumor is also a rough place to live, and its own surroundings keep throwing sparks at it. Tumors often grow faster than their blood supply can keep up, so their inner pockets run short of oxygen, sugar, and other nutrients:

• Too little oxygen: You might expect less oxygen to mean fewer sparks, but often the opposite happens. Struggling mitochondria leak more sparks when oxygen runs low. And when blood flow returns in fits and starts, the sudden rush of oxygen sets off another burst, much like a smoldering fire that flares up when someone opens a window.
• Too little sugar: Cells use sugar not only for energy but also to recharge their extinguishers. Glutathione and thioredoxin both depend on a helper molecule called NADPH, which cells make largely from sugar. When a tumor runs short of sugar, its extinguishers run low just when it needs them most.
• Inflamed, acidic surroundings: Immune cells drawn into a tumor release bursts of sparks, the same ones they use against germs. The tumor’s surroundings also tend to be inflamed and acidic, which adds to the stress.
• Seeds hiding in the hardest places: Cancer stem cells often shelter in the harshest, lowest-oxygen corners of a tumor. In normal stem cells, too many sparks push them to mature or wear out, and researchers think cancer stem cells face the same pressure. To stay “seeds,” they must keep their sparks very low, so a strong shield is not optional. It is a job requirement.
• The dangerous journey: When a cancer cell breaks loose to spread, it loses the anchor that keeps its metabolism running and faces heavy oxidative stress. In a study of human melanoma cells in mice, most cells that entered the bloodstream did not survive this stress. The rare cells that went on to spread had boosted their antioxidant defenses, and giving the mice antioxidants actually increased the spread.

The shield, then, is first of all survival gear for life in a harsh place. Its power to blunt treatment is almost a bonus the cancer gets for free, and that is why the same defenses show up again and again when treatments fail.

Five Shields You May Hear About

You may see these names on a lab report or hear them from your care team. Here is what each one does, in simple terms:

• Peroxiredoxins (PRDXs) are the first responders. They quickly mop up one of the most common sparks, hydrogen peroxide, before it can do damage. As you will see below, some tumors even release them into the space around the cancer.
• Glutathione (GSH) is the cell’s main, all-purpose extinguisher. It puts out sparks, and it can also latch onto some chemotherapy drugs so the cell can push them back out.
• Thioredoxin reductase (TrxR) runs a backup extinguisher system. If one system is blocked, the cancer cell can lean on the other, which is one reason cancer is so stubborn.
• Heme oxygenase-1 (HO-1) is a multitasker. It protects the cancer cell, and it also helps calm down the immune cells that would otherwise attack the tumor.
• NAD(P)H quinone oxidoreductase 1 (NQO1) is a cleanup enzyme that many tumors make in very large amounts. Interestingly, this can become a weakness, because researchers are designing drugs that trick NQO1 into harming the very cell that made it.

Cancer Stem Cells: The Seeds That Survive

Not every cancer cell is the same. A small group, called cancer stem cells, behave like seeds. After treatment clears most of a tumor, these seeds can quietly regrow it, which is a major reason cancer returns.

Research shows these seed cells carry an especially strong shield. They keep their sparks very low and stock up on extinguishers like glutathione. In one well-known breast cancer study, these low-spark cells withstood radiation better than ordinary tumor cells. That means the cells most likely to cause a relapse are often the best protected.

How the Shield Blunts Treatment

Many cancer treatments work, at least in part, by turning up the sparks inside cancer cells until they can no longer cope. A tumor with a thick shield can simply put out more of those fires. Doctors have long known this is true for chemotherapy and radiation. Newer research shows the same shield also weakens immunotherapy, targeted drugs, and hormone blockers, each in its own way.

Sometimes the shield protects the cell directly, by neutralizing sparks or pushing drugs out. Other times it works indirectly, by switching off the cell’s self-destruct programs or by disarming the immune system:

• Chemotherapy: Some chemotherapy drugs damage cancer cells by creating sparks. A well-shielded cell can put out those sparks, and glutathione can grab certain drugs so the cell can pump them back out before they do their job.
• Radiation: Radiation kills cancer largely by creating a flood of sparks that break the cell’s DNA. Tumors with their master switch stuck in the “on” position tend to resist radiation better. In one lung cancer study, tumors with this change were much more likely to regrow in the treated area.
• Immunotherapy: These treatments help your own immune cells, called T cells, attack the cancer. Here is the surprise: T cells actually need a small amount of sparks to switch on and do their job. A study published in September 2026 in the journal Science found that some tumors take advantage of this by releasing a peroxiredoxin called PRDX1 into the surrounding fluid. It mops up the very sparks the T cells need, a bit like soaking a match before it can be struck. The researchers call this a “redox checkpoint.” In mice, removing PRDX1 helped the immune system reject some tumors and made resistant tumors respond to checkpoint immunotherapy (drugs such as anti-PD-1 treatments). The researchers also found signs of PRDX1 in fluid taken from human tumors, though they have not yet tested this as a treatment in people. The shield also interferes with immunotherapy in other ways. Immune cells kill tumors partly by cutting off the cancer’s supply of glutathione building blocks, and a tumor with extra extinguishers can hold out longer. HO-1 adds to the problem by calming the immune cells around the tumor, so the attack is weaker.
• Targeted therapy: Targeted pills are designed to switch off a specific growth signal the cancer depends on. When that signal is cut, the cancer cell is thrown into chaos, its sparks often rise, and that alone can push it toward death. The shield steps in here as well. Through the NRF2 master switch, the cell calls up its backup extinguishers, the glutathione and thioredoxin systems. A second protector, FSP1, guards the cell’s outer wall from the “rusting” type of death known as ferroptosis. Together, these defenses let some cancer cells survive in a quiet, resting state even as the drug does exactly what it was designed to do. Researchers have found that these hardy survivors lean heavily on the glutathione shield to stay alive, and they are a common source of later resistance.
• Hormone blockers: Some breast and prostate cancers are fed by hormones, and hormone blockers work by cutting off that fuel. Starving a hormone-hungry cancer cell also stresses its energy furnaces (the mitochondria), which can throw off extra sparks. Surviving cancer cells often respond by building up antioxidant defenses and shielding themselves from ferroptosis. Researchers believe this acts as a survival buffer, keeping cells alive long enough to adapt and eventually grow without the hormone. It is one reason some hormone-driven cancers stop responding to treatment over time.

Dying Quietly: How the Shield Silences the Alarm

When a cancer cell dies, how it dies matters a great deal. Some deaths are quiet. The cell is tidied away, and the immune system never notices. Other deaths are loud. Scientists call this immunogenic cell death, a mouthful that simply means a death that gets the immune system’s attention.

A loud death works like a flare. As the cell dies, it raises an “eat me” flag on its surface and releases distress signals into its surroundings. These signals call in immune scouts, which pick up the remains, learn what the cancer looks like, and train T cells to hunt down the same cancer elsewhere in the body. In a sense, every loud death acts like a small, personal cancer vaccine.

Sparks are one of the main triggers that make a death loud. Much of this alarm signaling begins with oxidative stress in the cell’s protein-folding workshop (called the endoplasmic reticulum). Ferroptosis, the “rusting” death described earlier, may also sound the alarm. In one mouse study, cancer cells caught early in ferroptosis worked as a vaccine against the same cancer, though other studies suggest the picture is more complicated.

This is where the shield does quiet but serious harm. Your body does not wait for treatment to fight cancer. Every day, the harsh tumor environment and the immune system’s own attacks push some cancer cells toward death, and loud deaths keep the immune system alert. A thick antioxidant shield lets cancer cells either avoid dying altogether or die quietly, so the alarm never sounds. Over time, the immune system can lose track of the cancer.

The same thing can happen during treatment. Certain chemotherapy drugs and radiation work partly by causing loud deaths, turning the tumor into its own vaccine. Researchers have noted that changes inside cancer cells that block these alarm signals can contribute to treatment failure. By damping the sparks that trigger the alarm, the shield may help explain why.

So the shield does more than help cancer cells survive. It helps them stay hidden, both while they live and when they die.

Reasons for Hope

Here is the encouraging part. Once scientists understood this shield, they could target it. If a tumor depends on its extinguishers to survive, then lowering the shield could make standard treatments work better.

Researchers are testing several ways to do this. Some approaches lower the cancer’s glutathione, some block the backup thioredoxin system, and some push the tumor’s already high sparks past the breaking point. Others turn the cancer’s own NQO1 enzyme against it. Most of these approaches are still being studied, and they are meant to work alongside standard treatment, not replace it. Still, they show how understanding cancer’s defenses can open new doors.

A Word About Antioxidant Supplements

Once you understand the shield, a natural question follows: what happens when someone takes antioxidant pills during cancer care? Many people take them hoping to protect their healthy cells. The problem is that a pill cannot choose which cells it helps. Cancer cells are already hoarding extinguishers, and adding more may simply top off the tumor’s shield.

Think back to everything we have covered. Chemotherapy and radiation kill cancer partly with sparks. T cells need sparks to switch on. Cancer cells trying to spread often die from sparks along the way. Loud, alarm-sounding cancer cell deaths also depend on sparks. Each of these works in your favor, and extra antioxidants can blunt them.

One supplement deserves special mention. N-acetylcysteine, often sold as NAC, supplies the raw material cells use to build glutathione, the tumor’s main extinguisher. In mice with early lung cancer, NAC and vitamin E made tumors grow faster and shortened survival. In another mouse study described earlier, antioxidants helped melanoma cells survive the journey through the bloodstream and spread.

This concern is not just theory. It has shown up in studies of people:

• During radiation: In a trial of 540 people treated with radiation for head and neck cancer, those randomly given high-dose vitamin E and beta-carotene had milder side effects. But their cancer tended to return in the treated area more often, about 37% more, a borderline result. The researchers cautioned that high-dose antioxidants might weaken radiation.
• During chemotherapy: In a large study of women with breast cancer, those who took antioxidant supplements both before and during chemotherapy showed about a 41% higher risk of their cancer returning. This finding was also borderline, but it points in the same direction.
• In prevention: Antioxidant pills given to prevent cancer have backfired too. In two large trials, beta-carotene raised the risk of lung cancer among smokers by 18% in one and 28% in the other, and the second trial was stopped early. In another trial, men taking high-dose vitamin E had a 17% higher risk of developing prostate cancer.

Common Antioxidant Supplements

Antioxidants show up in far more products than most people realize. Below are some of the most common ones found in supplements. This list is not all-inclusive. Many multivitamins, “immune support” formulas, and greens powders combine several of these in a single product, so it pays to read labels carefully:

• Vitamins and minerals: Beta-carotene or vitamin A, selenium, vitamin C, vitamin E, and zinc. Selenium and zinc are not antioxidants themselves, but the body uses them to build its own antioxidant enzymes. Selenium, for example, is a building block of thioredoxin reductase, one of the five shields described above, and of a key glutathione enzyme that guards the cell’s outer wall.
• Plant extracts: Astaxanthin, bilberry, curcumin, grape seed extract, green tea extract (EGCG), lycopene, mixed polyphenols, Pycnogenol, quercetin, resveratrol, spirulina, and sulforaphane. Some of these, such as sulforaphane, work mainly by flipping on the NRF2 master switch, the same switch many tumors already have stuck in the “on” position.
• Cellular antioxidants: Alpha-lipoic acid, coenzyme Q10, glutathione, and N-acetylcysteine (NAC). These are the same kinds of molecules the shield itself is built from. Glutathione is the tumor’s main extinguisher, NAC supplies its raw material, and coenzyme Q10 is what the FSP1 protector uses to guard the cell’s outer wall against ferroptosis.

What about the plant compounds you may have read can fight cancer? Curcumin, green tea extract (EGCG), resveratrol, quercetin, and several others on this list have produced striking results in laboratory studies, and some can even turn into pro-oxidants that attack cancer cells. The catch is where those results come from. In a lab dish, cancer cells are bathed directly in high concentrations of the compound. Your body never sees anything close to that from a capsule.

Most oral antioxidants are poorly absorbed, and much of what does get in is quickly broken down by the gut and liver and cleared from the blood. Vitamin C shows how tight these limits are. Even with very large oral doses, blood levels hit a ceiling, while intravenous (IV) vitamin C can reach levels 30-70 times higher. That gap is why the pro-oxidant effects seen in the lab cannot be reproduced by swallowing pills. The small amount that does reach your bloodstream works as an antioxidant, on the same side as the tumor’s shield.

None of this means every supplement on this list is dangerous. Not every study shows harm, and results vary by cancer type, dose, and timing. Correcting a true deficiency, such as low vitamin C or selenium, is also very different from taking high doses. But when antioxidant pills offer little real pro-oxidant benefit and carry a genuine risk of reinforcing the shield, more is not better during cancer care.

The key is to talk with your care team before adding or stopping any supplement. A simple step is to bring every bottle you take to your next appointment, so every choice works with your treatment rather than against it.

Whole Foods Are a Different Story

Antioxidants in whole foods come in modest amounts, are absorbed in small quantities, and arrive packaged with fiber and many other helpful compounds. The benefits of a colorful, plant-rich diet come from that whole package, not from any single antioxidant, and it remains one of the best gifts you can give your body. So keep enjoying your fruits and vegetables.

The one exception is juicing. Removing the fiber lets you drink the antioxidants from many servings at once, concentrating the dose well beyond what you would get from eating the same foods. Heavy juicing starts to behave more like a supplement than a meal, so whole foods are the better choice.

The Bottom Line

Cancer cells live with a lot of internal fire in a harsh environment, so they build a thick shield of antioxidants to survive it. That same shield can help them withstand chemotherapy, radiation, immunotherapy, targeted drugs, and hormone blockers, and the hardy seed cells that cause relapse are often the best protected. The shield even helps dying cancer cells slip away quietly, without alerting the immune system.

Understanding this shield is not a reason for fear. It is a reason for hope, because every defense cancer relies on is also a potential weakness. Knowledge helps you ask better questions, and asking good questions with your care team is one of the most powerful steps you can take.

References

1. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994 Apr 14;330(15):1029-35.
2. Ambrosone CB, Zirpoli GR, Hutson AD, et al. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2020 Mar 10;38(8):804-814.
3. Bairati I, Meyer F, Gélinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005 Aug 20;23(24):5805-13.
4. Binkley MS, Jeon YJ, Nesselbush M, et al. KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. Cancer Discov. 2020 Dec;10(12):1826-1841.
5. DeNicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011 Jul 6;475(7354):106-9.
6. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009 Apr 9;458(7239):780-3.
7. Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019 Nov;575(7784):693-698.
8. Efimova I, Catanzaro E, Van der Meeren L, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 2020 Nov 13;8(2):e001369.
9. Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012 Mar 7;31(5):1062-79.
10. Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017 Nov 9;551(7679):247-250.
11. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12;306(14):1549-56.
12. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
13. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996 May 2;334(18):1150-5.
14. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004 Apr 6;140(7):533-7.
15. Piskounova E, Agathocleous M, Murphy MM, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015 Nov 12;527(7577):186-91.
16. Sayin VI, Ibrahim MX, Larsson E, et al. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med. 2014 Jan 29;6(221):221ra15.
17. Schafer ZT, Grassian AR, Song L, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature. 2009 Sep 3;461(7260):109-13.
18. Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019 May;569(7755):270-274.
19. Wesolowski AJ, et al. Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species. Science. 2026 Sep 3;393(6815):1036-1044.

This article is for education and does not replace personal medical advice. Please talk with your oncologist about any questions regarding your treatment, diet, or supplements.